Core Viewpoint - The company XinTiandi has received approval from the National Medical Products Administration for its drug "Vildagliptin Tablets," which is classified as a Category 4 chemical drug and is effective for the treatment of type 2 diabetes [1] Group 1: Drug Approval and Details - The drug Vildagliptin Tablets has been granted a registration certificate with a validity period of 24 months, expiring on July 21, 2030 [1] - The original developer of Vildagliptin is Novartis Pharmaceuticals, and it is marketed in China under the name "Jiaweile" [1] - Vildagliptin works by increasing the levels of incretin hormones, which helps to reduce blood glucose levels by decreasing liver glucose production [1] Group 2: Company Impact - The approval of Vildagliptin Tablets signifies that the product meets the necessary registration requirements, allowing the company to produce and sell the drug in the domestic market [1] - This approval will enhance the company's product portfolio and improve its market competitiveness [1]

Core Viewpoint - The company Xin Tiandi (301277.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Vildagliptin tablets, which are used for the treatment of type 2 diabetes [1] Group 1: Product Information - Vildagliptin is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, originally developed by Swiss pharmaceutical company Novartis, and marketed in China under the name "Jiaweile" [1] - The drug works by rapidly inhibiting DPP-4 activity, leading to increased levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhances the sensitivity of beta cells to glucose and promotes glucose-dependent insulin secretion [1] Group 2: Mechanism of Action - Vildagliptin increases the sensitivity of alpha cells to glucose, improving the alignment between glucose levels and glucagon secretion [1] - During hyperglycemia, Vildagliptin elevates the levels of intestinal glucagon-like peptides, increasing the insulin/glucagon ratio, which results in reduced hepatic glucose production and consequently lowers blood sugar levels [1]